401 related articles for article (PubMed ID: 33216236)
1. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
2. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
3. Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis.
Matsuda Y; Ishiwata T; Yoshimura H; Yamashita S; Ushijima T; Arai T
Pancreas; 2016 Jan; 45(1):93-100. PubMed ID: 26335012
[TBL] [Abstract][Full Text] [Related]
4. A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy.
Li J; Chen Y; Zeng L; Lian G; Chen S; Li Y; Yang K; Huang K
J Biomed Nanotechnol; 2016 Aug; 12(8):1654-66. PubMed ID: 29342344
[TBL] [Abstract][Full Text] [Related]
5. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
6. HIF1α-siRNA and gemcitabine combination-based GE-11 peptide antibody-targeted nanomedicine for enhanced therapeutic efficacy in pancreatic cancers.
Lin C; Hu Z; Yuan G; Su H; Zeng Y; Guo Z; Zhong F; Jiang K; He S
J Drug Target; 2019 Aug; 27(7):797-805. PubMed ID: 30481072
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
8. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
9. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Kang YW; Lee JE; Jung KH; Son MK; Shin SM; Kim SJ; Fang Z; Yan HH; Park JH; Han B; Cheon MJ; Woo MG; Lim JH; Kim YS; Hong SS
Cancer Lett; 2018 Dec; 438():174-186. PubMed ID: 30217561
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
[TBL] [Abstract][Full Text] [Related]
11. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Tokunaga Y; Liu D; Nakano J; Zhang X; Nii K; Go T; Huang CL; Yokomise H
Eur J Cancer; 2015 Nov; 51(16):2480-9. PubMed ID: 26254808
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
13. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer.
Zeng L; Li J; Wang Y; Qian C; Chen Y; Zhang Q; Wu W; Lin Z; Liang J; Shuai X; Huang K
Nanomedicine; 2014 Feb; 10(2):463-72. PubMed ID: 24028894
[TBL] [Abstract][Full Text] [Related]
14. Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer.
Das M; Li J; Bao M; Huang L
AAPS J; 2020 Jun; 22(4):88. PubMed ID: 32572645
[TBL] [Abstract][Full Text] [Related]
15. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Shimizu K; Nishiyama T; Hori Y
Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
18. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
Pei Y; Chen L; Huang Y; Wang J; Feng J; Xu M; Chen Y; Song Q; Jiang G; Gu X; Zhang Q; Gao X; Chen J
Small; 2019 Jun; 15(24):e1900631. PubMed ID: 31033217
[TBL] [Abstract][Full Text] [Related]
19. Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
Dalla Pozza E; Lerda C; Costanzo C; Donadelli M; Dando I; Zoratti E; Scupoli MT; Beghelli S; Scarpa A; Fattal E; Arpicco S; Palmieri M
Biochim Biophys Acta; 2013 May; 1828(5):1396-404. PubMed ID: 23384419
[TBL] [Abstract][Full Text] [Related]
20. [An experimental study of gemcitabine inducing pancreatic cancer cell apoptosis potentiated by nuclear factor-kappa B P65 siRNA].
Kong R; Sun B; Wang SJ; Pan SH; Wang G; Chen H; Xue DB; Jiang HC
Zhonghua Wai Ke Za Zhi; 2010 Jan; 48(2):128-33. PubMed ID: 20302733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
